Summary by Moomoo AI
SCICLONE PHARMA (SCICLONE PHARMA) announced on 19 April 2024 that its Chief Executive Officer, Peter Shao Chihwen, received 195,000 share options on 18 April 2024 under Rule 22 of the Hong Kong Code of Companies. The option has an exercise period from April 18, 2024 to April 18, 2030, at an exercise price of $7.8920 per share and an option amount of $0.0000. Following this transaction, Peter Shao Chihwen's total shares in Sai Pharma reached 2,740,000 shares. The transaction was conducted under the Company's Share Incentive Scheme and was conducted for its own account.